Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2013

View Archived Issues

Novartis prepares new protein kinase inhibitors

Initial results available from phase I/II study of indibulin in metastatic breast cancer

Iron chelator ameliorates experimental Alzheimer's disease

French scientists design novel DCL enzyme inhibitors

Merck & Co. presents new mGlu2 receptor agonists

U.S. scientists divulge novel cytochrome P450 1A2 inducers

Metabolex presents new GPBA receptor agonists

Novel compounds for autoimmune disorders patented

Ultragenyx inlicenses triheptanoin from Baylor Research Institute

BIKAM Pharmaceuticals prepares new opsin-2 ligands

Esperion's ETC-1002 lowers LDL cholesterol in phase II trial

GeoVax completes enrollment in phase I/II trial for HIV/AIDS vaccine

Dosing completed in phase III BromSite study

Phase II trial of NeoFuse stem cell product meets endpoints

Novel drug-eluting bioadhesive gel reduces inflammation in atherosclerotic plaques in vivo

Morphotek discloses results from phase III study in platinum-sensitive epithelial ovarian cancer

KaloBios begins phase II study of Humaneered PEGylated monoclonal antibody fragment

Topline data reported from phase II study of tivantinib in colorectal cancer

MSD suspends availability of Tredaptive

Evotec advances compound into preclinical development under collaboration with Ono

Mirabegron approved in Europe

European Commission approves use of Zytiga earlier in the treatment cycle

Biota synthesizes promising inhibitor of cell division protein FtsZ

FDA grants orphan drug designation to Telik's investigational treatment for MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...